Discovery of novel 1,2,4-thiadiazole derivatives as potent, orally active agonists of sphingosine 1-phosphate receptor subtype 1 (S1P 1)

Journal of Medicinal Chemistry

Volumn 55, Issue 9, 2012, Pages 4286-4296

  Ren, Feng ^a   Deng, Guanghui ^a   Wang, Hailong ^a   Luan, Linbo ^a   Meng, Qinghua ^a   Xu, Qiongfeng ^a   Xu, Heng ^a   Xu, Xuesong ^a   Zhang, Haibo ^a   Zhao, Baowei ^a   Li, Chengyong ^a   Guo, Taylor B ^a   Yang, Jiansong ^a   Zhang, Wei ^a   Zhao, Yonggang ^a   Jia, Qiantao ^a   Lu, Hongtao ^a   Xiang, Jia Ning ^a   Elliott, John D ^a   Lin, Xichen ^a  

^a GLAXOSMITHKLINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 ETHYL 3 [5 [4 ISOPROPOXY 3 (TRIFLUOROMETHYL) PHENYL] 1,2,4 THIADIAZOL 3 YL] AZETIDINE 3 CARBOXYLIC ACID; 1 [2 ETHYL 3 [5 [4 ISOPROPOXY 3 (TRIFLUOROMETHYL) PHENYL] 1,2,4 THIADIAZOL 3 YL] BENZYL] PIPERIDINE 4 CARBOXYLIC ACID; 1 [2 ETHYL 3 [5 [4 ISOPROPOXY 3 (TRIFLUOROMETHYL) PHENYL] 1,2,4 THIADIAZOL 3 YL] PHENETHYL] ) AZETIDINE 3 CARBOXYLIC ACID; 1 [2 ETHYL 3 [5 [4 ISOPROPOXY 3 (TRIFLUOROMETHYL) PHENYL] 1,2,4 THIADIAZOL 3 YL] PHENETHYL] PIPERIDINE 4 CARBOXYLIC ACID; 1 [3 [5 (3 CHLORO 4 ISOPROPOXYPHENYL) 1,2,4 THIADIAZOL 3 YL] 2 ETHYLBENZYL] AZETIDINE 3 CARBOXYLIC ACID; 1 [3 [5 (3 CHLORO 4 ISOPROPOXYPHENYL) 1,2,4 THIADIAZOL 3 YL] 2 ETHYLPHENETHYL] AZETIDINE 3 CARBOXYLIC ACID; 1 [3 [5 (3 CHLORO 4 ISOPROPOXYPHENYL) 1,2,4 THIADIAZOL 3 YL] 2 ETHYLPHENETHYL] PIPERIDINE 4 CARBOXYLIC ACID; 1 [3 [5 (3 CYANO 4 ISOBUTYLPHENYL) 1,2,4 THIADIAZOL 3 YL] 2 ETHYLBENZYL] AZETIDINE 3 CARBOXYLIC ACID; 1 [3 [5 (3 CYANO 4 ISOBUTYLPHENYL) 1,2,4 THIADIAZOL 3 YL] 2 ETHYLPHENETHYL] AZETIDINE 3 CARBOXYLIC ACID; 1 [3 [5 (3 CYANO 4 ISOBUTYLPHENYL) 1,2,4 THIADIAZOL 3 YL] 2 ETHYLPHENETHYL] PIPERIDINE 4 CARBOXYLIC ACID; 1,2,4 THIADIAZOLE DERIVATIVE; 2 [2 ETHYL 3 [5 [4 ISOPROPOXY 3 (TRIFLUOROMETHYL) PHENYL] 1,2,4 THIADIAZOL 3 YL] PHENYL] ACETALDEHYDE; 2 [3 [5 (3 CHLORO 4 ISOPROPOXYPHENYL) 1,2,4THIADIAZOL 3 YL] 2 ETHYLPHENYL] ACETALDEHYDE; 2 [[2 ETHYL 3 [5 [4 ISOPROPOXY 3 (TRIFLUOROMETHYL) PHENYL] 1,2,4 THIADIAZOL 3 YL] BENZYL] (METHYL) AMINO] 2 METHYLPROPANOIC ACID; 2 [[2 ETHYL 3 [5 [4 ISOPROPOXY 3 (TRIFLUOROMETHYL) PHENYL] 1,2,4 THIADIAZOL 3 YL] BENZYL] (METHYL) AMINO] ACETIC ACID; 2 [[2 ETHYL 3 [5 [4 ISOPROPOXY 3 (TRIFLUOROMETHYL) PHENYL] 1,2,4 THIADIAZOL 3 YL] PHENETHYL] (METHYL) AMINO] ACETIC ACID; 2 [[2 ETHYL 3 [5 [4 ISOPROPOXY 3 (TRIFLUOROMETHYL) PHENYL] 1,2,4 THIADIAZOL 3 YL] PHENETHYL] AMINO] ACETIC ACID; 2 ETHYL 3 [5 [4 ISOPROPOXY 3 (TRIFLUOROMETHYL) PHENYL] 1,2,4 THIADIAZOL 3 YL) BENZALDEHYDE; 3 [2 ETHYL 3 (2 METHOXYVINYL) PHENYL] 5 [4 ISOPROPOXY 3 (TRIFLUOROMETHYL) PHENYL]1,2,4 THIADIAZOLE; 3 [5 (3 CHLORO 4 ISOPROPOXYPHENYL) 1,2,4 THIADIAZOL 3 YL) 2 ETHYLBENZALDEHYDE; 3 BROMO 5 (3 CHLORO 4 ISOPROPOXYPHENYL) 1,2,4 THIADIAZOLE; 3 BROMO 5 (4 ISOPROPOXY 3 (TRIFLUOROMETHYL)PHENYL) 1,2,4 THIADIAZOLE; 5 (3 BROMO 1,2,4 THIADIAZOL 5 YL) 2 ISOBUTYLBENZONITRILE; 5 (3 CHLORO 4 ISOPROPOXYPHENYL) 3 [2 ETHYL 3 (2 METHOXYVINYL) PHENYL] 1,2,4 THIADIAZOLE; 5 [3 (2 ETHYL 3 FORMYLPHENYL) 1,2,4 THIADIAZOL 5 YL] 2 ISOBUTYLBENZONITRILE; 5 [3 [2 ETHYL 3 (2 METHOXYVINYL) PHENYL] 1,2,4 THIADIAZOL 5 YL] 2 ISOBUTYLBENZONITRILE; 5 [3 [2 ETHYL 3 (2 OXOETHYL) PHENYL] 1,2,4 THIADIAZOL 5 YL] 2 ISOBUTYLBENZONITRILE; FINGOLIMOD; SPHINGOSINE 1 PHOSPHATE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DEVELOPMENT; DRUG PENETRATION; DRUG POTENCY; DRUG STRUCTURE; IN VITRO STUDY; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; RAT;

ADMINISTRATION, ORAL; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE COUNT; LYMPHOCYTES; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICE, INBRED C57BL; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RATS; RECEPTORS, LYSOSPHINGOLIPID; SPECIFIC PATHOGEN-FREE ORGANISMS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP; THIADIAZOLES;

EID: 84861088360     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm2016107     Document Type: Article

References (35)

1. Compston, A.; Coles, A. Multiple Sclerosis Lancet 2002, 359, 1221-1231 (Pubitemid 34304266)
2. Sorbera, L. A.; Dulsat, C.; Rosa, E. Therapeutic Targets for Multiple Sclerosis Drugs Future 2009, 34, 405-417
3. Brinkmann, V.; Billich, A.; Baumruker, T.; Heining, P.; Schmouder, R.; Francis, G.; Aradhye, S.; Burtin, P. Fingolimod (FTY720): Discovery and Development of an Oral Drug to Treat Multiple Sclerosis Nat. Rev. 2010, 9, 883-897
4. Lublin, F. D.; Baier, M.; Cutter, G. Effect of Relapses on Development of Residual Deficit in Multiple Sclerosis Neurology 2003, 61, 1528-1532 (Pubitemid 37505574)
5. Brinkmann, V.; Cyster, J. G.; Hla, T. FTY720: Sphingosine 1-Phosphate Receptor-1 in the Control of Lymphocyte Egress and Endothelial Barrier Function Am. J. Transplant. 2004, 4, 1019-1025 (Pubitemid 38868590)
6. Miron, V. E.; Ludwin, S. K.; Darlington, P. J.; Jarjour, A. A.; Soliven, B.; Kennedy, T. E.; Antel, J. P. Fingolimod (FTY720) Enhances Remyelination following Demyelination of Organotypic Cerebellar Slices Am. J. Pathol. 2010, 176, 2682-2694
7. Choi, J. W.; Herr, D.; Kennedy, G.; Chun, J. Astrocytic Sphingosine 1-Phosphate (S1P) Receptor Subtype 1 Signalling Influences Levels of S1P and Cytokines during Experimental Autoimmune Encephalomyelitis and Fingolimod (FTY720) Intervention Mult. Scler. 2009, 15, S58
8. Mandala, S.; Hajdu, R.; Bergstrom, J.; Quackenbush, E.; Xie, J.; Milligan, J.; Thornton, R.; Shei, G.-J.; Card, D.; Keohane, C.; Rosenbach, M.; Hale, J.; Lynch, C. L.; Rupprecht, K.; Parsons, W.; Rosen, H. Alteration of Lymphocyte Trafficking by Sphingosine-1 Phosphate Receptor Agonists Science 2002, 296, 346-349 (Pubitemid 34303689)
9. Brinkmann, V.; Davis, M. D.; Heise, C. E.; Albert, R.; Cottens, S.; Hof, R.; Bruns, C.; Prieschl, E.; Baumruker, T.; Hiestand, P.; Foster, C. A.; Zollinger, M.; Lynch, K. R. The Immune Modulator FTY720 Targets Sphingosine-1-Phosphate Receptors J. Biol. Chem. 2002, 277, 21453-21457 (Pubitemid 34952287)
10. Verzijl, D.; Peters, S. L. M.; Alewijnse, A. E. Sphingosine-1-Phosphate Receptors: Zooming in on Ligand-Induced Intracellular Trafficking and Its Functional Implications Mol. Cell 2010, 29, 99-104
11. Matloubian, M.; Lo, C. G.; Cinamon, G.; Lesneski, M. J.; Xu, Y.; Brinkmann, V.; Allende, M. L.; Proia, R. L.; Cyster, J. G. Lymphocyte Egress from Thymus and Peripheral Lymphoid Organs Is Dependent on S1P Receptor 1 Nature 2004, 427, 355-360 (Pubitemid 38133663)
12. 1, on T-Cells Controls Thymic Emigration J. Biol. Chem. 2004, 279, 15396-15401 (Pubitemid 38618938)
13. Mizugishi, K.; Yamashita, T.; Olivera, A.; Miller, G. F.; Spiegel, S.; Proia, R. L. Essential Role for Sphingosine Kinases in Neural and Vascular Development Mol. Cell. Biol. 2005, 25, 11113-11121 (Pubitemid 41747151)
14. Kovarik, J. M.; Lu, M.; Riviere, G.; Barbet, I.; Maton, S.; Goldwater, D. R.; Schmouder, R. L. The Effect on Heart Rate of Combining Single-Dose Fingolimod with Steady-State Atenolol or Diltiazem in Healthy Subjects Eur. J. Clin. Pharmacol. 2008, 64, 457-463
15. Schmouder, R.; Serra, D.; Wang, Y.; Kovarik, J. M.; Dimarco, J.; Hunt, T. L.; Bastien, M.-C. FTY720: Placebo-Controlled Study of the Effect on Cardiac Rate and Rhythm in Healthy Subjects J. Clin. Pharmacol. 2006, 46, 895-904 (Pubitemid 44050826)
16. Forrest, M.; Sun, S.-Y.; Hajdu, R.; Bergstrom, J.; Card, D.; Doherty, G.; Hale, J.; Keohane, C.; Meyers, C.; Milligan, J.; Mills, S.; Nomura, N.; Rosen, H.; Rosenbach, M.; Shei, G.-J.; Singer, I. I.; Tiam, M.; West, S.; White, V.; Xie, J.; Proia, R. L.; Mandala, S. Immune Cell Regulation and Cardiovascular Effects of Sphingosine-1-Phosphate Receptor Agonists in Rodents Are Mediated via Distinct Receptor Subtypes J. Pharmacol. Exp. Ther. 2004, 309, 758-768 (Pubitemid 38542632)
17. 3, Respectively, Regulate Lymphocyte Recirculation and Heart Rate J. Biol. Chem. 2004, 279, 13839-13848 (Pubitemid 38468916)
18. Shimizu, H.; Takahashi, M.; Kaneko, T.; Murakami, T.; Hakamata, Y.; Kudou, S.; Kishi, T.; Fukuchi, K.; Iwanami, S.; Kuriyama, K.; Yasue, T.; Enosawa, S.; Matsumoto, K.; Takeyoshi, I.; Morishita, Y.; Kobayashi, E. KRP-203, a Novel Synthetic Immunosuppressant, Prolongs Graft Survival and Attenuates Chronic Rejection in Rat Skin and Heart Allografts Circulation 2005, 111, 222-229 (Pubitemid 40139735)
19. Li, W.; Luo, S.; Smith, H. T.; Tse, F. L. S. Quantitative Determination of BAF312, a S1P-R Modulator, in Human Urine by LC-MS/MS: Prevention and Recovery of Lost Analyte Due to Container Surface Adsorption J. Chromatogr. B 2010, 878, 583-589 and references therein
20. 1 Receptor Agonists J. Med. Chem. 2010, 53, 4198-4211
21. 1 Receptor Agonists for the Treatment of Inflammatory and Autoimmune Disorders Expert Opin. Ther. Pat. 2008, 18, 1141-1159 and references therein
22. Yan, L.; Budhu, R.; Huo, P.; Lynch, C. L.; Hale, J. J.; Mills, S. G.; Hajdu, R.; Keohane, C. A.; Rosenbach, M. J.; Milligan, J. A.; Shei, G.-J.; Chrebet, G.; Bergstrom, J.; Card, D.; Mandala, S. M. 2-Aryl(pyrrolidin-4-yl) acetic Acids Are Potent Agonists of Sphingosine-1-Phosphate (S1P) Receptors Bioorg. Med. Chem. Lett. 2006, 16, 3564-3568 (Pubitemid 43777118)
23. 1) with High Selectivity against All Other Known S1P Receptor Subtypes Bioorg. Med. Chem. Lett. 2006, 16, 3679-3683 (Pubitemid 44137242)
24. 1) Receptor Bioorg. Med. Chem. Lett. 2006, 16, 3684-3687 (Pubitemid 44164271)
25. 1) with Enhanced Pharmacokinetic Properties Bioorg. Med. Chem. Lett. 2007, 17, 828-831 (Pubitemid 46108548)
26. Deng, G.; Lin, X.; Meng, Q.; Ren, F.; Xiang, J.; Xu, H.; Zhao, B.; Zhang, H. Preparation of 5-Membered Heteroaryl Derivatives as Sphingosine 1-Phosphate Receptor Agonists. WO2010148649(A1), 2010. Mouse experimental autoimmune encephalomyelitis (EAE) data are unpublished results from this laboratory.
27. 14C]oxadiazole (SQ18,506): 1. Reductive Cleavage of the 1,2,4-Oxadiazole Ring Xenobiotica 1973, 3, 97-102
28. Dalvie, D. K.; Kalgutkar, A. S.; Khojasteh-Bakht, S. C.; Obach, R. S.; O'Donnell, J. P. Biotransformation Reactions of Five-Membered Aromatic Heterocyclic Rings Chem. Res. Toxicol. 2002, 15, 269-299 (Pubitemid 34241365)
29. Sendzik, M.; Hui, H. C. Environmentally Friendly and Efficient: Iron-Mediated Reduction of 3-Methyl-5-aryl-1,2,4-oxadiazoles to Benzamidines Tetrahedron Lett. 2003, 44, 8697-8700 (Pubitemid 37324781)
30. Bird, C. W. A New Aromaticity Index and Its Application to Five-membered Ring Heterocycles Tetrahedron 1985, 41, 1409-1414
31. Bird, C. W. The Application of a New Aromaticity Index to Six-Membered Ring Heterocycles Tetrahedron 1986, 42, 89-92
32. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and Computational Approaches To Estimate Solubility and Permeability in Drug Discovery and Development Settings Adv. Drug Delivery Rev. 1997, 23, 3-25 (Pubitemid 27046991)
33. Fessey, R. E.; Austin, R. P.; Barton, P.; Davis, A. M.; Wenlock, M. C. The Role of Plasma Protein Binding in Drug Discovery. In Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, LogP2004: 3rd Lipophilicity Symposium, Zurich, Switzerland, Feb 29-Mar 4, 2004; Testa, B., et al., Eds.; Wiley-VCH: Weinheim, Germany, 2006; pp 119-141.
34. For EAE protocol, refer to the following: Liu, X.; Leung, L.; Wang, C.; Tan, Z.; Wang, J.; Guo, T. B.; Fang, L.; Zhao, Y.; Wan, B.; Qin, X.; Lu, L.; Li, R.; Pan, H.; Song, M.; Liu, A.; Hong, J.; Lu, H.; Zhang, J. Z. Crucial Role of Interleukin-7 in T Helper Type 17 Survival and Expansion in Autoimmune Disease Nat. Med. 2010, 16, 191-197
35. 1) Receptor Agonists. WO2011113309(A1), 2011.